ArticleBMC cancer2026

Efficacy and tolerability of CDK 4/6 inhibitors in HR-positive HER2-negative de novo metastatic breast cancer patients aged ≥ 70 years.

Muhammed Mustafa Atci et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.